<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03129412</url>
  </required_header>
  <id_info>
    <org_study_id>NPC-Oligo-M</org_study_id>
    <nct_id>NCT03129412</nct_id>
  </id_info>
  <brief_title>Oligo-metastases NPC Patients Received Radiation for Primary Tumors and Treatments for Metastatic Lesions</brief_title>
  <official_title>The Clinical Curative Efficacy and Side Effect of Oligo-metastases Nasopharyngeal Carcinoma Patients Received Radical Radiation for Primary Tumors and Treatments for Metastatic Lesions</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhejiang Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhejiang Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Oligo-metastases NPC patients received radiation for primary tumors and treatments for
      metastatic lesions.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The patients enrolled will received 4-6 cycles chemotherapy at first.Then, radical
      radiotherapy for nasopharyngeal tumors and local treatments for oligometastatic lesions will
      assigned to those patients. The efficacy and side-effect will be evaluated and analyzed.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 14, 2017</start_date>
  <completion_date type="Anticipated">April 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">April 23, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of diagnosis until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 36 months</time_frame>
    <description>Events of death caused by any reasons</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progress free survival</measure>
    <time_frame>From date of diagnosis until the date of first documented progression, assessed up to 36 months</time_frame>
    <description>adverse event including death, recurrence and metastases.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">64</enrollment>
  <condition>Nasopharyngeal Cancer</condition>
  <condition>Neoplasm Metastasis</condition>
  <arm_group>
    <arm_group_label>Arm 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4-6 cycles chemotherapy and radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will assigned to those who got PR,SD after chemotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>radical radiotherapy</intervention_name>
    <description>radical radiotherapy for primary tumors were given. Appropriate treatments for olio-metastatic lesions will be assigned to those who got PR,SD after chemotherapy.</description>
    <arm_group_label>Arm 1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Histologically conformed initial non-keratinizing squamous carcinoma in nasopharynx.

          2. Clinical stages,T1-4N0-3M1，IVc(AJCC 2010).

          3. The metastatic lesions ≤5 and metastatic organs ≤2

          4. Karnofsky scores ＞70

          5. Normal hemodynamic indices before the recruitment (including white blood cell
             count&gt;4.0×109/L, neutrophil count&gt;1.5×109/L, platelet count &gt;100×109/L,
             hemoglobin≥90g/l, normal liver/kidney function).

          6. Informed consent signed.

        Exclusion Criteria:

          1. Histologically conformed initial keratinizing carcinoma or others.

          2. The metastatic lesions ＞5 or metastatic organs ＞2.

          3. Any severe complications contraindicated chemotherapy or radiotherapy.

          4. History of malignant tumors.

          5. Pregnant or nursing women.

          6. History of radiotherapy or chemotherpy in head and neck regions.

          7. Patients refused the informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shuang Huang, Dr</last_name>
    <phone>+8618258111085</phone>
    <email>huangshuang@zjcc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhejiang Cancer Hospital</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuan Huang</last_name>
      <phone>+8618258111085</phone>
      <email>huangshuang@zjcc.org.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 12, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 26, 2017</study_first_posted>
  <last_update_submitted>April 25, 2017</last_update_submitted>
  <last_update_submitted_qc>April 25, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 26, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasm Metastasis</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

